Læknablaðið - 15.09.1992, Blaðsíða 31

LÆKNABLAÐIÐ
291
a cellular enzyme-linked immunosorbent assay. J Lab
Clin Med 1987; 109: 434-40.
12. Cutler SJ, Ederer F. Maximum utilization of the life-
table method in analyzing survival. J Chronic Dis
1958; 8; 699-713.
13. Steen VD, Ovens GR, Fino GJ, et al. Pulmonary
involvement in systemic sclerosis (scleroderma).
Arthritis Rheum 1984; 28: 759-67.
14. Ferri C, Bemini L, Bongomi MG, et al. Noninvasive
evaluation of cardiac dysrythmias and their
relationship with multisystemic symptoms in
progressive systemic sclerosis patients. Arthritis
Rheum 1985; 28: 1259-66.
15. Medsger TA jr. Masi AT, Rodnan GP, et al. Survival
with systemic sclerosis (scleroderma) a life-table
analysis of clinical and demografic factors in 309
patients. Ann Intem Med 1971; 75: 369-76.
16. Blom-Bulow B. Functional and therapeutic studies in
progressive systemic sclerosis. Lund, 1983. (Thesis).
17. Rocco VK, Hurd ER. Scleroderma and scleroderma-
like disorders. Semin Arthritis Rheum 1986; 16: 22-
69.
18. Sigurðsson V, Steinsson K, Geirsson AJ,
Guðmundsson S. Fjölkerfabandvefssjúkdómar á
íslandi. Læknablaðið 1992; 78: 243-9.
19. Steen VD, Medsger TA. Epidemiology and natural
history of systemic sclerosis. In: Rheumatic Disease
Clinics of North America, Scleroderma. WB Sauders,
1990.
20. Steen VD, Conte C, Medsger TA jr, et al. Twenty-
year incidence survey of systemic sclerosis
(scleroderma). Arthritis Rheum 1988; 31: 57.
21. Maricq HR, Weinrich MC, Keil JE, LeRoy EC.
Prevalence of Raynaud’s phenomenon in the general
population. J Chronic Dis 1986; 39: 423-7.
22. Erasmus LD. Scleroderma in coalminers on the
Witwatersrand with particular reference to pulmonary
manifestations. S Afr J Lab Clin Med 1957; 3: 209-
31.
23. Black CM, Walker AE, Cattogio LJ, et al. Genetic
suseptibility to scleroderma-like syndrome induced by
vinylchlorid. Lancet 1983; 1/8: 53-5.
24. Martinez-Tello FJ, Navas-Palacios JJ, Ricoy JR, et
al. Pathology of a new toxic oil syndrome caused by
ingestion of adulterated oil in Spain. Virchows Arc A
1982; 397: 261.
25. Silver RM. Clinical aspcts of systemic sclerosis
(scleroderma). Ann Rheum Dis 1991; 50: 854-61.
26. Kahaleh MB. Vascular disease in scleroderma.
Endothelial T lymphocyte-fibroblast interactions.
In: Rheumatic Disease Clinics of North America,
Scleroderma. WB Saunders, 1990.
27. Penning CA, Cunningham J, French MAH, et al.
Antibody-dependent cellular cytotoxicity of human
vascular endothelium in systemic sclerosis. Clin Exp
Immunol 1984; 57: 548-56.